GlassScriptPhysician profile
Marvin Mesa
NPI 1265925408
$4,251.26
in general payments reported to CMS, 2019-2025
29 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $888 · 2022: $438 · 2023: $1,052 · 2024: $866 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,725 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,724.68 |
| Education | $199.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $971.64 | 2021-2025 | Myrbetriq, Padcev, Xtandi |
| Janssen Biotech, INC. | $796.23 | 2021-2025 | Erleada, Talvey, Balversa |
| Pfizer INC. | $354.27 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $212.32 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Eisai INC. | $208.10 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $187.92 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $169.51 | 2024-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Sumitomo Pharma America, INC. | $130.56 | 2023 | Gemtesa |
| Urovant Sciences INC | $122.36 | 2021-2022 | |
| Abbvie INC. | $111.18 | 2021-2023 | |
| Coloplast Corp | $105.76 | 2021-2025 | Speedicath |
| Seagen INC. | $99.95 | 2025 | |
| Janssen Scientific Affairs, LLC | $96.80 | 2025 | Erleada, Akeega |
| Lilly USA, LLC | $86.74 | 2024-2025 | Verzenio, Jaypirca, Omvoh |
| Dendreon Pharmaceuticals LLC | $76.51 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $73.02 | 2024-2025 | Opdivo |
| Endo Pharmaceuticals INC. | $67.58 | 2023 | Xiaflex |
| Array Biopharma INC | $67.39 | 2024-2025 | Mektovi, Tukysa, Braftovi |
| Caris Mpi, INC. | $48.39 | 2025 | Mi Cancer Seek |
| Myriad Genetic Laboratories, INC. | $39.37 | 2021-2023 | Prolaris |
| 180 Medical, INC. | $36.36 | 2021-2023 | Gentlecath |
| Tolmar Pharmaceuticals, INC. | $34.17 | 2021 | |
| Novartis Pharmaceuticals Corporation | $29.16 | 2022-2023 | |
| Azurity Pharmaceuticals, INC. | $24.31 | 2025 | Azmiro |
| Sun Pharmaceutical Industries INC. | $22.58 | 2024 | |
| Agios Pharmaceuticals, INC. | $22.47 | 2024 | Pyrukynd |
| Clarus Therapeutics INC. | $19.14 | 2021 | |
| Antares Pharma, INC. | $18.92 | 2023 | Tlando, Xyosted, Nocdurna |
| Olympus America INC. | $18.55 | 2023 | Soltive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Mesa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.